Pulmonx (NASDAQ:LUNG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 [Yahoo! Finance]
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Why The Pulmonx LUNG Narrative Is Shifting After Target Cut And Leadership Return [Yahoo! Finance]
How Leadership Changes And Analyst Revisions Are Shaping Pulmonx's Valuation Story [Yahoo! Finance]